At a glance
ClinicalIndex Comparison RecordPhase 1Unknown· 40 target
Drug / intervention
GR2002 injectionbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Phase Ib Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of GR2002 Injection in Patients With Moderate to Severe Atopic Dermatitis
Genrix (Shanghai) Biopharmaceutical Co., Ltd.·interventional·Posted Dec 18, 2023·Updated Dec 18, 2023
In Brief
A Phase 1 clinical trial evaluating GR2002 injection for Atopic Dermatitis. Targeting 40 participants across 1 site.
Detailed Summary
This is a randomized, double-blind, placebo-controlled Phase Ib clinical trial evaluating the safety tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of GR2002 Injection in patients with moderate to severe atopic dermatitis. The dosing period was 12 weeks and followed up to 20 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesChina
Collaborators--
Timeline
Phase 1UnknownOverdue
202420252026
Enrollment StartDec 2023
First PostedDec 2023
Primary CompletionOct 2024
TodayJul 2026
First PostedDec 18, 2023
Enrollment StartDec 1, 2023
Primary CompletionOct 1, 2024
TodayJul 1, 2026
Enrollment to primary: 10 monthsPosted 2.5 years ago
Interventions
GR2002 injectionbiological
TSLP monoclonal antibody